Summary A pathological review was carried out on 600 patients with breast carcinoma entered into the 'Nolvadex'* Adjuvant Trial Organisation (NATO) study. The tumours were graded histologically and these results were compared with the oestrogen receptor (ER) status of the tumours, the numbers of recurrences and the length of survival of the patients. It was found that histological grading was predictive both in terms of events and survival, and correlates significantly with oestrogen receptor status; within histological grades I and II, patients receiving 'Nolvadex' had fewer events and deaths compared with patients in the control group. For patients with grade III tumours qualitatively it was in the same direction as the benefit obtained in patients with grade I and II tumours.
The patients recruited into a multicentre randomised controlled trial of tamoxifen ('Nolvadex') as a single adjuvant agent after mastectomy for early breast cancer have now been followed up for a maximum of 8 years ('Nolvadex' Adjuvant Trial Organisation (NATO), 1983 , 1985 , 1987 Organisation, 1983 Organisation, , 1985 . The result based on the ER analysis is counter-intuitive and therefore requires closer scrutiny. Attempts to dismiss the result as an artifact of faulty ER assay are not valid because the proportion of patients with ER positive tumours and the prognostic significance of a positive result parallel the data from many other large-scale studies (McGuire et al., 1975; Wallgren et al., 1984; Rose et al., 1985) . A more fertile line to pursue might be to consider the ER status as predicting quantitative differences in outcome rather than absolute qualitative differences. If this is the case, the correct result might be obscured by power considerations in a trial reduced to less than 600 cases where ER status of the primary tumour was known. As histological grade has been shown to correlate with prognosis and ER status in breast carcinoma (Bloom & Richardson, 1957; Bloom, 1962; Elston et al., 1980) (1957) in which tubular differentiation, nuclear pleomorphism and the presence of mitotic figures are each scored on a three point scale; cases with a score of 3-5 being allocated to Grade, I 6-7 to Grade II and 8-9 to Grade III.
Statistical analysis of the outcome was based on an 'intention to treat' policy using two separate end points. One end point was first recurrence of breast cancer (including cancer in the contralateral breast) or death without previously confirmed recurrence of disease ('events'). The other end point was overall survival. Log rank tests (Peto et al., 1976 (Peto et al., , 1977 were used to assess the statistical significance of the difference between treatment groups and between histological grades with respect to time to an event and overall survival time.
Results
Of the 1,285 patients entered in the NATO trial, slides were eventually received from 600 patients. Grading was possible in 546 cases (91%) and in 256 cases (47%) where tumour oestrogen receptor had also been measured. 282 of the 546 patients (52%) had been treated with tamoxifen.
The treated and untreated groups were similar in the distribution of tumour grade (Table I) . Tables IIA and IIB and Figure 1 show that histological grade was predictive for both events (P<0.0001) and deaths (P<0.0001). In the case where the oestrogen receptor content of the primary tumour was known in addition to the histological grade, (Table III) Figure 1 Comparison of histological grades. reveal that the observed to expected ratios are less than one in each of the treated groups indicating a treatment benefit in each tumour grade, although the difference in ratios between the treated and untreated groups is less for grade III than for either grades I or II.
Discussion
These results demonstrate very clearly that histological grading is predictive in terms of events and survival. These findings agree with results from other large studies concerning the prognosis of breast cancer (Wallgren et al., 1984; Rose et al., 1985) . Histological grading is often criticised because of its subjective nature and observer variation. Furthermore, the histological specimen itself may not be truly representative of the tumour as a whole. Nevertheless, with one observer studying all 546 sections we are confident that the subsequent interpretations of the data are secure. The relatively high number of grade I tumours in the sample might reflect random bias of tissue samples available for analysis or the disproportionate number of node negative cases in the trial as a whole (NATO, 1983) .
For the purpose of classifying oestradiol receptor status in this study, a cut-off point of 30fmolmg-1 cytosol protein was chosen as this represented a median value for the trial as a whole. Using lower values of cut-off to discriminate between positive and negative tumours does not materially affect the result, although it weakens statistical comparisons. At a 30fmolmg-1 cytosol protein cut-off point there is little difference between grades I and II but histological grade III tumours were almost twice as likely to be receptor negative than receptor positive, according to our definition. There was thus a clear statistically significant difference in ER content between grades I and II combined and grades III, adding further support to previous observations showing a correlation between histological grade and oestrogen receptor status (Elston et al., 1980) .
The results indicate that adjuvant tamoxifen may be of greatest benefit in the better differentiated (Grades I and II) tumours which are also the tumours likely to have a greater oestradiol receptor content. This result provides some support for the notion that the differences in outcome from adjuvant tamoxifen between different biological subsets of breast cancer is one of magnitude rather than kind. Paradoxically, the overview analysis of all trials of adjuvant tamoxifen (Peto, personal communication) has suggested that the relative risk reductions, based on lymph node status, are constant, thus the greater the risk of relapse the greater the absolute benefit of adjuvant tamoxifen.
Clearly, however, such detailed advice to clinicians must await analyses on histological grading from other adjuvant tamoxifen trials.
